Back Back
Expert Analysis

CME

Key Studies in Myeloma: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™

Released: March 22, 2021

Expiration: March 21, 2022

Shaji K. Kumar
Shaji K. Kumar, MD
Sagar Lonial
Sagar Lonial, MD, FACP
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

References

  1. Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232-242.
  2. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv52-iv61.
  3. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782-1791.
  4. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431-442.
  5. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936-945.
  6. ClinicalTrials.gov. Study comparing daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) versus lenalidomide, bortezomib, and dexamethasone (RVd) in subjects with newly diagnosed multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT02874742. Accessed March 5, 2021.
  7. Kaufman JL, Laubach JP, Sborov D, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 12 months of maintenance therapy. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 549.
  8. Joseph NS, Kaufman JL, Dodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:1928-1937.
  9. ClinicalTrials.gov. A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia). Available at: https://clinicaltrials.gov/ct2/show/NCT02541383. Accessed March 5, 2021.
  10. Daratumumab package insert. Horsham, PA: Janssen Biotech; 2020.
  11. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104-2115.
  12. Kumar SK, Facon T, Usmani SZ, et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia study. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 2276.
  13. ClinicalTrials.gov. Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in participants with previously untreated multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT02252172. Accessed March 5, 2021.
  14. Jimenez-Zepeda VH, Duggan P, Neri P, et al. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma. Ann Hematol. 2017;96:431-439.
  15. Mateos MV, Richardson PG, Dimopoulos MA, et al. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015;90:314-319.
  16. Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33:3459-3466.
  17. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621-1634.
  18. Ixazomib package insert. Cambridge, MA: Takeda Pharmaceutical Co; 2020.
  19. Facon T, Venner CP, Bahlis N, et al. The phase 3 TOURMALINE-MM2 trial: oral ixazomib, lenalidomide, and dexamethasone (IRd) vs placebo-Rd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 551.
  20. ClinicalTrials.gov. IXAZOMIB plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with newly diagnosed multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT01850524. Accessed March 5, 2021.
  21. Avet-Loiseau H, Bahlis NJ, Chng W, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130:2610-2618.
  22. Mateos M, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370-380.
  23. US Food and Drug Administration. FDA approves daratumumab and hyaluronidase-fijh for multiple myeloma. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma. Accessed March 5, 2021.
  24. Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) alone in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 412.
  25. ClinicalTrials.gov. Comparison of pomalidomide and dexamethasone with or without daratumumab in subjects with relapsed or refractory multiple myeloma previously treated with lenalidomide and a proteasome inhibitor/daratumumab/pomalidomide/dexamethasone vs pomalidomide/dexamethasone (EMN14). Available at: https://clinicaltrials.gov/ct2/show/NCT03180736. Accessed March 5, 2021.
  26. Siegel DS, Schiller GJ, Song KW, et al. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol. 2020;188:501.
  27. Tai Y-T, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155-165.
  28. Chook YM, Fung HYJ. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:52-61.
  29. Parikh K, Cang S, Sekri A, et al. Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents. J Hematol Oncol. 2014;7:78.
  30. Gravina GL, Mancini A, Sanita P, et al. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941.
  31. Argueta C, Kashyap T, Klebanov B, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget. 2018;9:25529-25544.
  32. Selinexor package insert. Newton, MA: Karyopharm Therapeutics; 2020.
  33. Chen CI, Bahlis N, Gasparetto C, et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Program and abstracts of the 2019 ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, Florida. Abstract 141.
  34. Chen CI, Bahlis N, Gasparetto C, et al. Selinexor in combination with pomalidomide and dexamethasone (SPd) for treatment of patients with relapsed refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 726.
  35. ClinicalTrials.gov. Selinexor and backbone treatments of multiple myeloma patients (STOMP). Available at: https://clinicaltrials.gov/ct2/show/NCT02343042. Accessed March 5, 2021.
  36. Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187-1199.
  37. Sheikh S, Lebel E, Trudel S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. Future Oncol. 2020;16:2783-2798.
  38. Belantamab mafodotin package insert. Brentford, UK: GlaxoSmithKline; 2020.
  39. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207-221.
  40. ClinicalTrials.gov. A study to investigate the efficacy and safety of two doses of GSK2857916 in participants with multiple myeloma who have failed prior treatment with an anti-CD38 antibody. Available at: https://clinicaltrials.gov/ct2/show/NCT03525678. Accessed March 5, 2020.
  41. Lonial S, Lee HC, Badros AZ, et al. DREAMM-2: single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM)—1-year outcomes by prior therapies. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 1417.
  42. Ferron-Brady G, Rathi C, Collins J, et al. Exposure–response (E-R) for ocular safety endpoints for belantamab mafodotin (belamaf), a B-cell maturation antigen (BCMA)-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM) in the DREAMM-2 study. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 1420.
  43. US Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed March 5, 2021.
  44. Nooka AK, Stockerl-Goldstein K, Quach H, et al. DREAMM-6: safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASCO Annual Meeting; May 29-31, 2020. Abstract 8502.
  45. Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 1419.
  46. Ghandi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164:811-821.
  47. Trudel S, McCurdy A, Sutherland HJ, et al. Part 1 results of a dose finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide (POM) and dexamethasone (DEX) for the treatment of relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 725.
  48. ClinicalTrials.gov. Multi-center study of GSK2857916 in combination with pomalidomide and dex. Available at: https://clinicaltrials.gov/ct2/show/NCT03715478. Accessed March 5, 2021.
  49. Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34:1197-1201.
  50. Matyskiela ME, Zhang W, Man H-W, et al. A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos. J Med Chem. 2018;61:535-542.
  51. Amatangelo M, Bjorklund C, Kang J, et al. Preclinical and Translational support for clinical development of iberdomide in combination with proteasome inhibitors: mechanism of synergy in clinical trial CC-220-MM-001. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 1358.
  52. Amatangelo M, Bjorklund C, Ma P, et al. Preclinical and translational data support development of iberdomide in combination with CD38- and SLAMF7-directed monoclonal antibodies: evidence for rational combinations. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 1359.
  53. Van De Donk NWCJ, Popat R, Larsen J, et al. First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 724.
  54. ClinicalTrials.gov. A study to determine dose, safety, tolerability and efficacy of CC-220 monotherapy, and in combination with other treatments in subjects with multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT02773030. Accessed March 5, 2021.
  55. Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Program and abstracts of the 2019 ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, Florida. Abstract 577.
  56. Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 177.
  57. ClinicalTrials.gov. A phase 1b-2, open-label study of JNJ-68284528, a chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA in subjects with relapsed or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03548207. Accessed March 5, 2021.
  58. Raje N, Berdeja J, Lin Yi, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726-1737.
  59. Alsina M, Shah N, Raje NS, et al. Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T Cell phenotypes. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 130.
  60. ClinicalTrials.gov. A phase 1 study of bb21217, an anti-BCMA CAR T cell drug product, in relapsed and/or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03274219. Accessed March 5, 2021.
  61. Costello CL, Cohen AD, Patel KK, et al. Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 134.
  62. ClinicalTrials.gov. Open-label, multicenter, phase 1 study to assess the safety of P BCMA-101 in subjects with relapsed/refractory multiple myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME). Available at: https://clinicaltrials.gov/ct2/show/NCT03288493. Accessed March 5, 2021.
  63. Mailankody S, Matous JV, Liedtke M, et al. Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 129.
  64. ClinicalTrials.gov. A single-arm, open-label, phase 1 study of the safety, efficacy, and cellular kinetics/pharmacodynamics of ALLO-715 to evaluate an anti-BCMA allogeneic CAR T cell therapy with or without nirogacestat in subjects with relapsed/refractory multiple myeloma. available at: https://clinicaltrials.gov/ct2/show/nct04093596. accessed march 5, 2021.
  65. Harrison SJ, Minnema MC, Lee HC, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 181.
  66. ClinicalTrials.gov. A phase 1/2 open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 701 monotherapy, or in combination with pomalidomide, with and without dexamethasone in subjects with relapsed or refractory multiple myeloma (ParadigMM-1B). Available at: https://clinicaltrials.gov/ct2/show/NCT03287908. Accessed March 5, 2021.
  67. Garfall AL, Usmani SZ, Mateos M, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 180.
  68. ClincalTrials.gov. A phase 1, first-in-human, open-label, dose escalation study of teclistamab, a humanized BCMA x CD3 DuoBody antibody in subjects with relapsed or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03145181. Accessed March 5, 2021.
  69. Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 291.
  70. ClinicalTrials.gov. Phase 1/2 FIH study of REGN5458 (anti-BCMA x Anti-CD3 bispecific antibody) in patients with relapsed or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03761108. Accessed March 5, 2021
  71. Kumar SK, Migkou M, Bhutani M, et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma. Program and abstracts of the 2020 ASH Annual Meeting and Exposition; December 5-8, 2020. Abstract 179.
  72. ClinicalTrials.gov. A phase 1, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of MEDI2228 in subjects with relapsed/refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03489525. Accessed March 5, 2021.
  73. Cohen AD, Harrison SJ, Krishnan A, et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma. Program and abstracts of the 2020 ASH Annual Meeting; December 5-8, 2020. Abstract 292.
  74. ClinicalTrials.gov. An open-label, multicenter, phase I trial evaluating the safety and pharmacokinetics of escalating doses of BFCR4350A in patients with relapsed or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03275103. Accessed March 5, 2021.
  75. Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:(485):eaau7746.
  76. Chari A, Berdeja JG, Oriol A, et al. A phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM). Program and abstracts of the 2020 ASH Annual Meeting; December 5-8, 2020. Abstract 290.
  77. ClinicalTrials.gov. A phase 1, first-in-human, open-label, dose escalation study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in subjects with relapsed or refractory multiple myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT03399799. Accessed March 5, 2021.

BACK | NEXT
Claim Certificate